Clinician-to-Clinician Update Clinician-to-Clinician Update

Pediatric Specialty Updates

June 2017

Ranked in the top 3 for IBD remission rates

University of Minnesota Masonic Children’s Hospital has retained its rank as a top tier care-network facility in the treatment of pediatric inflammatory bowel disease (IBD), achieving a 73% sustained clinical remission rate among its patients. Rankings reflect data reported from Improve Care Now, the largest national network of pediatric IBD treatment centers. IBD patients who are free of symptoms and maintain a strong growth and nutrient status for at least 1 year are identified as having achieved a sustained clinical remission.

Comprised of 91 centers, Improve Care Now brings together healthcare centers in the development and implementation of the latest in evidence-based care practices for Crohn’s disease and ulcerative colitis in infants, children, and adolescents. Members in the network collaborate with the goal of improving outcomes for patients with IBD. Over the past 6 years, the average rate of sustained clinical remissions among patients at ICN centers has risen from 40% to 51%. University of Minnesota Masonic Children’s Hospital was among the network’s first members.

June-2017-Peds-IBD-Consult-Spec-Updates-Image-in-Article
— IBD specialist Boris Sudel, MD, with care coordinators Shaundra Heimermann, RN, (left) and Stephanie Dahl, RN

Long-term studies of young IBD patients now enrolling

University of Minnesota Health pediatric gastroenterologists are participating in 2 multicenter, long-term studies evaluating patient outcomes related to therapies for pediatric inflammatory bowel disease (IBD). The observational registry DEVELOP tracks clinical status of these patient with attention to safety outcomes associated with infliximab and other prescribed IBD medications. Participants must be 17 years of age or younger with a confirmed diagnosis. All treatments will be decided by the treating physicians.

The study CAPE tracks long-term safety and effectiveness of adalimumab in pediatric patients with moderate to severe Crohn’s disease. The study will also track, as a reference group, patients prescribed azathioprine, 6-mercaptopurine, or methotrexate as immunosuppressive therapy. Participants must be 6 to 17 years of age and will be followed for up to 10 years. The study will record adverse effects as well as overall disease activity in participants. For information, contact Boris Sudel, MD, or Shannon Riggs at riggs049@umn.edu.

June-2017-Peds-IBD-Consult-Spec-Updates-Armfield-Matthew-pediatric-pain-clinic

Specialist joins new pain care clinic

Pediatric pain specialist Matthew A. Armfield, MD, MAEd, has joined University of Minnesota Masonic Children’s Hospital, helping lead efforts with the hospital’s Pediatric Pain and Advanced Complex Care Clinic. Armfield and clinic team members focus on medicinal and nonmedicinal treatment strategies to address both acute and chronic pain in children and adolescents who have complex medical problems, such as chronic pancreatitis or epidermolysis bullosa. The clinic functions as a part of the total pancreatectomy with islet auto transplant team; however, it plans to expand outpatient pain management services to other patient populations in the upcoming year. Armfield also has interest and expertise in management of acute pain in the inpatient setting, as well as in pain education at all levels of learning.

Related Articles

June 2017

Care Networks Improve Outcomes in Pediatric Inflammatory Bowel Disease

About 20 to 25% of all cases of IBD emerge in childhood. Coordinated care networks are speeding the identification of effective treatment and improving the overall health of these patients.

Continue reading

June 2017

Complication of Crohn’s Disease Treated with Microbiota Transplant

A young patient finds his symptoms reemerge and is diagnosed with a Clostridium difficile infection. Careful screening and a novel treatment help restore him to healthy growth and development.



Continue reading